• +1-646-491-9876
    • +91-20-67278686

    Search

    Anemia in Chronic Kidney Disease Pipeline Review H1 2017

    Anemia in Chronic Kidney Disease Pipeline Review H1 2017

    • Report Code ID: RW0001858673
    • Category Pharmaceuticals
    • No. of Pages 118
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.

    Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 8, 1, 1, 6, 1 and 1 respectively.

    Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Anemia in Chronic Kidney Disease (Renal Anemia) - Overview
    Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development
    3SBio Inc
    Aevi Genomic Medicine Inc
    Akebia Therapeutics Inc
    Amgen Inc
    Bayer AG
    Betta Pharmaceuticals Co Ltd
    Biocad
    CCM Duopharma Biotech Bhd
    Chong Kun Dang Pharmaceutical Corp
    CJ HealthCare Corp
    Dong-A Socio Holdings Co Ltd
    FibroGen Inc
    GlaxoSmithKline Plc
    Intas Pharmaceuticals Ltd
    Japan Tobacco Inc
    JCR Pharmaceuticals Co Ltd
    Jiangsu Hansoh Pharmaceutical Group Co Ltd
    Myungmoon pharmaceutical Co Ltd
    Novartis AG
    Panacea Biotec Ltd
    Pfizer Inc
    PharmaEssentia Corp
    PhytoHealth Corp
    Pieris Pharmaceuticals Inc
    Reliance Life Sciences Pvt Ltd
    Xenetic Biosciences Inc
    Zydus Cadila Healthcare Ltd
    Anemia in Chronic Kidney Disease (Renal Anemia) - Drug Profiles
    BPI-5014B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    daprodustat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EPO-018B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    epoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    epoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    epoetin zeta biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ErepoXen - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    erythropoietin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FG-2216 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HSA-EPO - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JTZ-951 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MDGN-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MMP-0101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    molidustat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PEG-EPO - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peg-EPO - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PEG-EPO - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegylated erythropoietin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PHEP-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRS-080 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Renal Anemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    roxadustat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SSS-06 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SSS-17 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    vadadustat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects
    Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products
    Anemia in Chronic Kidney Disease (Renal Anemia) - Product Development Milestones
    Featured News & Press Releases
    May 25, 2017: FDA Advisory Committee Recommends Approval Of Pfizer's Proposed Biosimilar To Epogen/Procrit Across All Indications
    May 24, 2017: Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents
    Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease
    Mar 28, 2017: Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease
    Nov 24, 2016: GSK starts phase III programme with daprodustat for anemia associated with chronic kidney disease
    Oct 10, 2016: Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen for Anemia
    Sep 26, 2016: Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia
    Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease
    Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients
    Aug 09, 2016: Kissei and JCR to Initiate a Phase III Clinical Trial of a Long-Acting Erythropoiesis-Stimulating Agent (Development Code: JR-131)
    Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease
    Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan
    Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment
    May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction
    May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by 3SBio Inc, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Aevi Genomic Medicine Inc, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Akebia Therapeutics Inc, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Amgen Inc, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Bayer AG, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Biocad, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CCM Duopharma Biotech Bhd, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CJ HealthCare Corp, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FibroGen Inc, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by GlaxoSmithKline Plc, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Japan Tobacco Inc, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Myungmoon pharmaceutical Co Ltd, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Novartis AG, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panacea Biotec Ltd, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pfizer Inc, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PharmaEssentia Corp, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PhytoHealth Corp, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pieris Pharmaceuticals Inc, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Xenetic Biosciences Inc, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H1 2017
    Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    3SBio Inc
    Aevi Genomic Medicine Inc
    Akebia Therapeutics Inc
    Amgen Inc
    Bayer AG
    Betta Pharmaceuticals Co Ltd
    Biocad
    CCM Duopharma Biotech Bhd
    Chong Kun Dang Pharmaceutical Corp
    CJ HealthCare Corp
    Dong-A Socio Holdings Co Ltd
    FibroGen Inc
    GlaxoSmithKline Plc
    Intas Pharmaceuticals Ltd
    Japan Tobacco Inc
    JCR Pharmaceuticals Co Ltd
    Jiangsu Hansoh Pharmaceutical Group Co Ltd
    Myungmoon pharmaceutical Co Ltd
    Novartis AG
    Panacea Biotec Ltd
    Pfizer Inc
    PharmaEssentia Corp
    PhytoHealth Corp
    Pieris Pharmaceuticals Inc
    Reliance Life Sciences Pvt Ltd
    Xenetic Biosciences Inc
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//anemia-in-chronic-kidney-disease-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//anemia-in-chronic-kidney-disease-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//anemia-in-chronic-kidney-disease-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments